Comparison of the clinical efficacy of twice-daily Ritalin® and once-daily Equasym™ XL with placebo in children with Attention Deficit/Hyperactivity Disorder
To compare the efficacy and safety of two methylphenidate (MPH) formulations—once-daily modified-release MPH (EqXL, Equasym™ XL) and twice-daily immediate-release methylphenidate (MPH-IR, Ritalin®)—and placebo in children with Attention Deficit/Hyperactivity Disorder (ADHD).
Children aged 6–12 years on a stable dose of MPH were randomized into a double-blind, three-arm, parallel-group, multi-center study and received 3 weeks of EqXL (20, 40, or 60 mg qd), MPH-IR (10, 20, or 30 mg bid) or placebo. Non-inferiority of EqXL to MPH-IR was assessed by the difference in the inattention/overactivity component of the overall teacher’s IOWA Conners’ Rating Scale on the last week of treatment (per protocol population). Safety was monitored by adverse events, laboratory parameters, vital signs, physical exam, and a Side Effect Rating Scale.
The lower 97.5% confidence interval bound of the difference between MPH groups fell above the non-inferiority margin (−1.5 points) not only during the last week of treatment but during all three treatment weeks. Both MPH-treatment groups experienced superior benefit when compared to placebo during all treatment weeks (P < 0.001). All treatments were well tolerated.
EqXL given once-daily was non-inferior to MPH-IR given twice-daily. Both treatments were superior to placebo in reducing ADHD symptoms.
KeywordsADHD methylphenidate children Metadate CD™ Equasym™ XL
- 2.American Psychiatric Association (1994) Diagnostic and statistical manual for mental disorders, 4th ed. American Psychiatric Association, Washington, DCGoogle Scholar
- 3.Almond BW, Tranner JL, Goffman HG (1999) The family is the patient: using family interviews in children’s medical care, 2nd ed. Williams & Wilkins, Baltimore, MDGoogle Scholar
- 5.Zentall SS (1993) Research on the educational implications of Attention deficit hyperactivity disorder. Exceptional Children 60(2):143–153Google Scholar
- 6.Cutting LE, Koth CW, Mahone EM, Denckla MB (2003) Evidence for unexpected weaknesses in learning in children with attention-deficit/hyperactivity disorder without reading disabilities. J Learning Disabilities 36(3):257–267Google Scholar
- 7.Faraone S-V, Biederman J, Monuteaux MCl, Doyle AE, Seidman LJ (2001) A psychometric measure of learning disability predicts educational failure four years later in boys with attention-deficit hyperactivity disorder. J Attention Disorders 4(4):220–230Google Scholar
- 8.Maynard J, Tyler JL, Arnold M (1999) Co-occurrence of attention-deficit disorder and learning disability: an overview of research. J Instruct Psychol 26(3):183–187Google Scholar
- 17.National Institute of Health (2000) National Institutes of Health consensus development conference statement: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry 39:182–197Google Scholar
- 20.Pelham WE, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein MS, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE (1990) Relative efficacy of long-acting stimulants on children with Attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 86:226–237PubMedGoogle Scholar
- 22.Greenhill LL, Findling RL, Swanson JM, the MPH MR ADHD Study Group (2002) A double-blind, placebo-controlled study of modified-release methylphenidate in children with Attention-Deficit/Hyperactivity Disorder. Pediatrics 109(3)Google Scholar
- 24.Wigal SB, Sanchez DY, DeCory HH, D’Imperio JM, Swanson JM (2003) Selection of the optimal dose ratio for a controlled-delivery formulation of methylphenidate. J Appl Res 3:46–63Google Scholar
- 25.Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36(7):980–988PubMedCrossRefGoogle Scholar
- 26.Loney J, Milich R (1982) Hyperactivity, inattention, and aggression in clinical practice. In: Wolraich M, Routh DK (eds) Advances in development and behavioral pediatrics. JAI Press, Greenwich, CT, pp 113–147Google Scholar
- 27.Swanson J (1992) School based assessments and interventions for ADD students. K.C. Publishing, Irvine, CA Google Scholar
- 28.Guy W (1976) ECDEU Assessment manual for psychopharmacology, Revised. National Institute of Mental Health, U.S. Department of Health, Education and Welfare, Rockville, MD (Publ. No. 76-338)Google Scholar
- 31.Wolraich ML, Greenhill LL, Pelham W, Swanson J, Willens T, Palumbo D, Atkins M, McBurnett K, Bulkstein O, August G, in behalf of the Concerta Study Group (2001) Randomized, controlled trial of OROS methylphenidate once a day in children with Attention-deficit/Hyperactivity Disorder. Pediatrics 108(4):883–892PubMedCrossRefGoogle Scholar